Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice

References

• BongartzTSuttonAJSweetingMJBuchanIMattesonELMontoriVAnti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trialsJAMA2006295192275228516705109
   PubMed Web of Science ®Google Scholar
• DixonWGWatsonKLuntMHyrichKLSilmanAJSymmonsDPRates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics RegisterArthritis Rheum20065482368237616868999
   PubMed Web of Science ®Google Scholar
• EllerinTRubinRHWeinblattMEInfections and anti-tumor necrosis factor alpha therapyArthritis Rheum200348113013302214613261
   PubMed Web of Science ®Google Scholar
• SmittenALSimonTAHochbergMCSuissaSA meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritisArthritis Res Ther2008102R4518433475
   PubMed Web of Science ®Google Scholar
• TraceyDKlareskogLSassoEHSalfeldJGTakPPTumor necrosis factor antagonist mechanisms of action: a comprehensive reviewPharmacol Ther2008117224427918155297
   PubMed Web of Science ®Google Scholar
• World Health OrganizationGlobal Tuberculosis ReportWorld Health Organization2014 Available from: http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdfAccessed August 3, 2016
   Google Scholar
• MurrayCJLOrtbladKFGuinovartCGlobal, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013Lancet201438499471005107025059949
   PubMed Web of Science ®Google Scholar
• BadawiASayeghSSallamMThe global relationship between the prevalence of diabetes mellitus and incidence of tuberculosis: 2000–2012Glob J Health Sci20147218319125716376
   PubMedGoogle Scholar
• UdwadiaZFMehraCTuberculosis in IndiaBMJ2015350H108025805828
   PubMed Web of Science ®Google Scholar
• KeaneJGershonSWiseRPTuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agentN Engl J Med2001345151098110411596589
   PubMed Web of Science ®Google Scholar
• NacciFMatucci-CerinicMTuberculosis and other infections in the antitumour necrosis factor-alpha (anti-TNF-alpha) eraBest Pract Res Clin Rheumatol201125337538822100287
   PubMed Web of Science ®Google Scholar
• ByunJMLeeCKRheeSYRisks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitorScand J Gastroenterol201550331232025581784
   PubMed Web of Science ®Google Scholar
• YooIKChoungRSHyunJJIncidences of serious infections and tuberculosis among patients receiving anti-tumor necrosis factor-alpha therapyYonsei Med J201455244244824532516
   PubMed Web of Science ®Google Scholar
• TubachFSalmonDRavaudPRisk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registryArthritis Rheum20096071884189419565495
   PubMed Web of Science ®Google Scholar
• HammoudehMAlarfajAChenDYDjoudiHYouseifEZhuJSafety of tumor necrosis factor inhibitors use for rheumatoid arthritis and ankylosing spondylitis in Africa, the Middle East, and Asia: focus on severe infections and tuberculosisClin Rheumatol201332329330023242389
   PubMed Web of Science ®Google Scholar
• KeWMChenLSParngIMChenWWOnAWRisk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in TaiwanInt J Tuberc Lung Dis201317121590159524200274
   PubMed Web of Science ®Google Scholar
• MokCCChanKYLeeKLTamLSLeeKWThe Hong Kong Society of RheumatologyFactors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics RegistryInt J Rheum Dis201417s318
   Google Scholar
• KimEMUhmWSBaeSCYooDHKimTHIncidence of tuberculosis among Korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockersJ Rheumatol201138102218222321844149
   PubMed Web of Science ®Google Scholar
• KwonMSungMKwonY-JActive tuberculosis risk with tumor necrosis factor inhibitors after treating latent tuberculosisJ Clin Rheumatol2014202687324561408
   PubMed Web of Science ®Google Scholar
• NavarraSVTangBLuLRisk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in AsiaInt J Rheum Dis201417329129824131578
   PubMed Web of Science ®Google Scholar
• ToKWReinoJJGYooDHTamLSTumour necrosis factor antagonist and tuberculosis in patients with rheumatoid arthritis: an Asian perspectiveRespirology201318576577323627398
   PubMed Web of Science ®Google Scholar
• ChenDYShenGHChenYMChenHHHsiehCWLanJLBiphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFalpha inhibitors: the utility of IFNgamma assayAnn Rheum Dis201271223123722021896
   PubMed Web of Science ®Google Scholar
• GardamMAKeystoneECMenziesRAnti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical managementLancet Infect Dis20033314815512614731
   PubMed Web of Science ®Google Scholar
• FabroniCGoriAPrignanoFLottiTA severe complication of anti-TNF alfa treatmentG Ital Dermatol Venereol2010145677577721139554
   PubMed Web of Science ®Google Scholar
• CagatayTAydinMSunmezSFollow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosisRheumatol Int201030111459146319844718
   PubMed Web of Science ®Google Scholar
• HeDBaiFZhangSHigh incidence of tuberculosis infection in rheumatic diseases and impact for chemoprophylactic prevention of tuberculosis activation during biologics therapyClin Vaccine Immunol201320684284723554465
   PubMedGoogle Scholar
• KurtOKKurtBTalayFIntermediate to long-term followup results of INH chemoprophylaxis prior to anti-TNF-alpha therapy in a high-risk area for tuberculosisWien Klin Wochenschr201312519–2061662024061693
   PubMed Web of Science ®Google Scholar
• Sanchez-MoyaAIDaudenEIncidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patientsJ Eur Acad Dermatol Venereol201125673073321564322
   PubMed Web of Science ®Google Scholar
• TomšičMRotarŽThe frequency of tuberculosis chemoprophylaxis prior to TNF-α inhibitor treatment, and the incidence tuberculosis infection using a two-step screening algorithm for latent tuberculosis infection: data from the BioRx.si registryAnn Rheum Dis201271111909191122805974
   PubMed Web of Science ®Google Scholar
• Gómez-ReinoJJCarmonaLValverdeVRMolaEMMonteroMDTreatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance reportArthritis Rheum20034882122212712905464
   PubMed Web of Science ®Google Scholar
• LalvaniAMillingtonKAScreening for tuberculosis infection prior to initiation of anti-TNF therapyAutoimmun Rev20088214715218706526
   PubMed Web of Science ®Google Scholar
• ForgetEJMenziesDAdverse reactions to first-line antituberculosis drugsExpert Opin Drug Saf20065223124916503745
   PubMed Web of Science ®Google Scholar
• NienhausARingshausenFCCostaJTSchablonATripodiDIFN-gamma release assay versus tuberculin skin test for monitoring TB infection in healthcare workersExpert Rev Anti Infect Ther2013111374823428101
   PubMed Web of Science ®Google Scholar
• ChenDYShenGHHsiehTYHsiehCWLanJLEffectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapyArthritis Rheum200859680080618512714
   PubMed Web of Science ®Google Scholar
• ChiuHYHsuehPRTsaiTFClinical experience of QuantiFERON®-TB gold testing in patients with psoriasis treated with tumour necrosis factor blockers in TaiwanBr J Dermatol2011164355355921083541
   PubMed Web of Science ®Google Scholar
• Karataş ToğralAMuştu KoryürekÖŞahinMBulutCYağciSEkşioğluHMAssociation of clinical properties and compatibility of the QuantiFERON-TB Gold In-Tube test with the tuberculin skin test in patients with psoriasisInt J Dermatol201555662963326498894
   PubMed Web of Science ®Google Scholar
• SinganayagamAManalanKSridharSEvaluation of screening methods for identification of patients with chronic rheumatological disease requiring tuberculosis chemoprophylaxis prior to commencement of TNF-α antagonist therapyThorax2013681095596123976779
   PubMed Web of Science ®Google Scholar
• Martyn-SimmonsCLMeeJBKirkhamBWGrovesRWMilburnHJEvaluating the use of the interferon-γ response to Mycobacterium tuberculosis-specific antigens in patients with psoriasis prior to antitumour necrosis factor-α therapy: a prospective head-to-head cross-sectional studyBr J Dermatol201316851012101823278714
   PubMed Web of Science ®Google Scholar
• AsklingJForedCMBrandtLRisk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in SwedenArthritis Rheum20055271986199215986370
   PubMed Web of Science ®Google Scholar
• DixonWGHyrichKLWatsonKDDrug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)Ann Rheum Dis201069352252819854715
   PubMed Web of Science ®Google Scholar
• EmerJJFrankelAZeichnerJAA practical approach to monitoring patients on biological agents for the treatment of psoriasisJ Clin Aesthet Dermatol2010382026
   Google Scholar
• CagatayTKilicaslanZCagatayPTNF-alpha antagonist therapy modify the tuberculin skin test responseRheumatol Int20113191147115120349071
   PubMed Web of Science ®Google Scholar
• O’SheaMKFletcherTEBeechingNJTuberculin skin testing and treatment modulates interferon-gamma release assay results for latent tuberculosis in migrantsPLoS One201495e9736624816576
   PubMed Web of Science ®Google Scholar
• Mohd HanafiahKGroegerJFlaxmanADWiersmaSTGlobal epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalenceHepatology20135741333134223172780
   PubMed Web of Science ®Google Scholar
• Díez-PadrisaNCastellanosLGPAHO Viral Hepatitis Working GroupViral hepatitis in Latin America and the Caribbean: a public health challengeRev Panam Salud Publica201334427528124301739
   PubMed Web of Science ®Google Scholar
• SzaboSMBibbyMYuanYThe epidemiologic burden of hepatitis C virus infection in Latin AmericaAnn Hepatol201211562363522947522
   PubMed Web of Science ®Google Scholar
• DiehlAMCytokine regulation of liver injury and repairImmunol Rev200017416017110807515
   PubMed Web of Science ®Google Scholar
• ElsammakMRefaiWElsawafAAbdel-FattahIAbd ElattiEGhazalAElevated serum tumor necrosis factor alpha and ferritin may contribute to the insulin resistance found in HCV positive Egyptian patientsCurr Med Res Opin200521452753315899101
   PubMed Web of Science ®Google Scholar
• Gutierrez-ReyesGLopez-OrtalPSixtosSEffect of pentoxifylline on levels of pro-inflammatory cytokines during chronic hepatitis CScand J Immunol200663646146716764700
   PubMed Web of Science ®Google Scholar
• KishiharaYHayashiJYoshimuraEYamajiKNakashimaKKashiwagiSIL-1 beta and TNF-alpha produced by peripheral blood mononuclear cells before and during interferon therapy in patients with chronic hepatitis CDig Dis Sci19964123153218601375
   PubMed Web of Science ®Google Scholar
• LecubeAHernándezCGenescàJSimóRProinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patientsDiabetes Care20062951096110116644643
   PubMed Web of Science ®Google Scholar
• MendozaECPaglieroniTGZeldisJBDecreased phorbol myristate acetate-induced release of tumor necrosis factor-α and interleukin-lβ from peripheral blood monocytes of patients chronically infected with hepatitis C virusJ Infect Dis199617448428448843226
   PubMed Web of Science ®Google Scholar
• BallantiEConigliaroPChimentiMSUse of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patientsDrug Dev Res201475suppl 1S42S4525381975
   PubMed Web of Science ®Google Scholar
• CostaLCasoFAttenoMLong-term safety of anti-TNF-alpha in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patientsClin Rheumatol201433227327623975363
   PubMed Web of Science ®Google Scholar
• FerriCFerraccioliGFerrariDSafety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infectionJ Rheumatol200835101944194918688917
   PubMed Web of Science ®Google Scholar
• IannoneFLa MontagnaGBagnatoGGremeseEGiardinaARLapadulaGSafety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trialJ Rheumatol201441228629224429167
   PubMed Web of Science ®Google Scholar
• PetersonJRHsuFCSimkinPAWenerMHEffect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infectionAnn Rheum Dis200362111078108214583571
   PubMed Web of Science ®Google Scholar
• PrignanoFRicceriFPescitelliLZanieriFLottiTTumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patientsBr J Dermatol2011164364564721375517
   PubMed Web of Science ®Google Scholar
• Nordgaard-LassenIDahlerupJFBelardEGuidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatmentDan Med J2012597C448022759856
   PubMed Web of Science ®Google Scholar
• PompiliMBiolatoMMieleLGriecoATumor necrosis factor-alpha inhibitors and chronic hepatitis C: a comprehensive literature reviewWorld J Gastroenterol201319447867787324307780
   PubMed Web of Science ®Google Scholar
• BrunassoAMGPuntoniMGuliaAMassoneCSafety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic reviewRheumatology20115091700171121690185
   PubMed Web of Science ®Google Scholar
• GiannittiCBellisaiFFerriCGaleazziMTreatment strategies for a patient with rheumatoid arthritis and hepatitis CExpert Opin Pharmacother200910457958719284361
   PubMed Web of Science ®Google Scholar
• MurdacaGSpanòFContatoreMGuastallaAMagnaniOPuppoFEfficacy and safety of etanercept in chronic immune-mediated diseaseExpert Opin Drug Saf201413564966124654562
   PubMed Web of Science ®Google Scholar
• ViganoMDegasperiEAghemoALamperticoPColomboMAnti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical managementExpert Opin Biol Ther201212219320722188392
   PubMed Web of Science ®Google Scholar
• ChenYMChenHHChenYHA comparison of safety profiles of tumour necrosis factor alpha inhibitors and rituximab therapy in patients with rheumatoid arthritis and chronic hepatitis CAnn Rheum Dis201574362662725452310
   PubMed Web of Science ®Google Scholar
• SinghJAFurstDEBharatA2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care Res (Hoboken)201264562563922473917
   PubMed Web of Science ®Google Scholar
• World Health Organization [webpage on the Internet]Hepatitis B Fact SheetWorld Health Organization2015 Available from: http://www.who.int/mediacentre/factsheets/fs204/en/Accessed August 3, 2016
   Google Scholar
• RomanSJose-AbregoAFierroNAHepatitis B virus infection in Latin America: a genomic medicine approachWorld J Gastroenterol201420237181719624966588
   PubMed Web of Science ®Google Scholar
• CoppolaNAlessioLPisaturoMHepatitis B virus infection in immigrant populationsWorld J Hepatol20157302955296126730274
   PubMedGoogle Scholar
• GuidottiLGIshikawaTHobbsMVMatzkeBSchreiberRChisariFVIntracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytesImmunity19964125368574849
   PubMed Web of Science ®Google Scholar
• CharpinCGuisSColsonPSafety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patientsArthritis Res Ther2009116R17919941642
   PubMed Web of Science ®Google Scholar
• VassilopoulosDCalabreseLHManagement of rheumatic disease with comorbid HBV or HCV infectionNat Rev Rheumatol20128634835722565315
   PubMed Web of Science ®Google Scholar
• VentoSCainelliFLonghiMSReactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issueLancet Oncol20023633334012107020
   PubMed Web of Science ®Google Scholar
• HoofnagleJHReactivation of hepatitis BHepatology2009495 supplS156S16519399803
   PubMed Web of Science ®Google Scholar
• YeoWChanHLHepatitis B virus reactivation associated with anti-neoplastic therapyJ Gastroenterol Hepatol2013281313723020594
   PubMed Web of Science ®Google Scholar
• ChungSJKimJKParkMCParkYBLeeSKReactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapyJ Rheumatol200936112416242019797507
   PubMed Web of Science ®Google Scholar
• LanJLChenYMHsiehTYKinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapyAnn Rheum Dis201170101719172521719446
   PubMed Web of Science ®Google Scholar
• LeeYHBaeSCSongGGHepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapyClin Exp Rheumatol2013311118121
   PubMed Web of Science ®Google Scholar
• LeeYHBaeS-CSongGGHepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDsInt J Rheum Dis201316552753124164839
   PubMed Web of Science ®Google Scholar
• Pérez-AlvarezRDíaz-LagaresCGarcía-HernándezFHepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 casesMedicine (Baltimore)201190635937122033451
   PubMed Web of Science ®Google Scholar
• VassilopoulosDApostolopoulouAHadziyannisELong-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infectionAnn Rheum Dis20106971352135520472596
   PubMed Web of Science ®Google Scholar
• YeHZhangXWMuRAnti-TNF therapy in patients with HBV infection–analysis of 87 patients with inflammatory arthritisClin Rheumatol201433111912324077913
   PubMed Web of Science ®Google Scholar
• KalyoncuUEmmungilHOnatAMCurrent antiviral practice and course of Hepatitis B virus infection in inflammatory arthritis: a multicentric observational study (A + HBV study)Eur J Rheumatol20152414915427708953
   PubMedGoogle Scholar
• ZhangXZhangFWuDSafety of infliximab therapy in rheumatoid arthritis patients with previous exposure to hepatitis B virusInt J Rheum Dis201316440841223992260
   PubMed Web of Science ®Google Scholar
• CalabreseLHZeinNVassilopoulosDSafety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infectionAnn Rheum Dis200463suppl 2ii18ii2415479865
   PubMedGoogle Scholar
• HwangJPLokASFManagement of patients with hepatitis B who require immunosuppressive therapyNat Rev Gastroenterol Hepatol201411420921924247262
   PubMed Web of Science ®Google Scholar
• MastroianniCMLichtnerMCittonRCurrent trends in management of hepatitis B virus reactivation in the biologic therapy eraWorld J Gastroenterol201117343881388722025876
   PubMed Web of Science ®Google Scholar
• NardFDTodoertiMGrossoVRisk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: extending perspective from old to newer drugsWorld J Hepatol20157334436125848463
   PubMed Web of Science ®Google Scholar
• KaradağÖKaşifoğluTÖzerBViral hepatitis screening guideline before biological drug use in rheumatic patientsEur J Rheumatol201631252827708965
   PubMedGoogle Scholar
• AiJWZhangSRuanQLThe risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-alpha antagonist: a metaanalysis of both randomized controlled trials and registry/cohort studiesJ Rheumatol201542122229223726472414
   PubMed Web of Science ®Google Scholar
• CalabreseLHCacoubPPFor patients with rheumatic disease and hepatitis C infection: the end of interferonRMD Open201511e00000826509045
   PubMedGoogle Scholar
• IannoneFCantiniFLapadulaGDiagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendationsJ Rheumatol Suppl201491414624788999
   PubMedGoogle Scholar
• LokASMcMahonBJChronic hepatitis BHepatology200745250753917256718
   PubMed Web of Science ®Google Scholar
• TerraultNABzowejNHChangKMHwangJPJonasMMMuradMHAASLD guidelines for treatment of chronic hepatitis BHepatology201663126128326566064
   PubMed Web of Science ®Google Scholar
• VallsVEnaJShort-course treatment of latent tuberculosis infection in patients with rheumatic conditions proposed for anti-TNF therapyClin Rheumatol2015341293424464437
   PubMed Web of Science ®Google Scholar